Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arcellx
Biotech
ASH: Gilead-Arcellx data build CAR-T's case in advanced myeloma
Arcellx's new data on a Gilead-partnered CAR-T show durable results and best-in-class potential for advanced multiple myeloma, analysts said.
Gabrielle Masson
Nov 5, 2024 3:08pm
NIH to invest another $515M over 4 years for long COVID research
Feb 15, 2024 10:57am
Gilead hands Arcellx $285M to expand BCMA cell therapy deal
Nov 15, 2023 10:00am
FDA lifts hold on Gilead's CAR-T as Arcellx sheds light on death
Aug 15, 2023 8:32am
FDA puts Gilead's $225M BCMA CAR-T on hold over patient death
Jun 20, 2023 6:15am
ASH: BCMA battle heats up as Gracell dazzles with 100% ORR in MM
Dec 12, 2022 5:55am
